Cardiovascular Benefits of GLP-1 Receptor Agonists in Obesity and Heart Failure: The treatment of obesity is evolving with the emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs), which offer significant cardiovascular benefits for patients with obesity and concurrent cardiovascular disease or diabetes. Prevention of Heart Failure in Patients with Obesity: Historically, the safety and efficacy of GLP-1RAs in heart failure (HF) were unclear, but recent evidence suggests they are safe and potentially effective, especially in heart failure with preserved ejection fraction (HFpEF). Treatment of Obesity in Patients with HF: Obesity is an independent risk factor for HF development, and lifestyle modifications have been shown to reduce this risk. GLP-1RAs, such as semaglutide, have demonstrated substantial weight loss and reduced cardiovascular events in patients with diabetes, obesity, and cardiovascular disease. Although physical activity and diet have modest effects on weight loss in HF patients, combining them yields better results. Bariatric surgery shows promise but carries risks, particularly for heart failure with reduced ejection fraction (HFrEF) patients. Evidence is limited regarding the weight loss effects of guideline-directed medical therapies for HF. While early studies raised concerns about GLP-1RAs in HF, recent data indicate they may be safe and beneficial for both HFpEF and HFrEF. However, larger trials are needed to confirm these findings. Future Directions: Ongoing and future research aims to validate the safety and efficacy of GLP-1RAs in broader HF populations, potentially offering new avenues for obesity and HF management.